Table 1

Clinical characteristics, haemodynamic variables, laboratory parameters and antithrombotic therapies in addition to DOACs at baseline

UDOAC n=72IDOAC n=60P value
Age, years (mean±SD)74±978±80.04
Males, n (%)53 (73.6)43 (71.7)0.80
STEMI, n (%)30 (41.7)8 (13.3)0.0003
Body mass index (mean±SD)27.7±4.727.7±4.60.95
Active smokers, n (%)10 (13.9)7 (11.7)0.58
Diabetes mellitus, n (%)25 (34.7)25 (41.7)0.41
Hypertension, n (%)64 (88.9)51 (85.0)0.51
Hypercholesterolaemia, n (%)42 (58.3)34 (56.7)0.16
Peripheral artery disease, n (%)11 (15.3)4 (6.7)0.21
Previous stroke/TIA, n (%)18 (25.0)9 (15.0)0.16
History of heart failure, n (%)14 (19.4)10 (16.7)0.68
Prior MI, n (%)22 (30.6)19 (31.7)0.89
Previous PCI/CABG, n (%)28 (38.9)22 (36.7)0.79
History of major bleeding, n (%)3 (4.2)2 (3.3)0.80
Chronic kidney disease, n (%)19 (26.4)11 (18.3)0.54
CHA2DS2-VASc (mean±SD)3.8±1.73.9±1.30.89
HAS BLEED (mean±SD)2.5±1.02.5±0.90.96
Ejection fraction, % (mean±SD)47.4±9.745.1±12.50.40
eGFR, mL/min (mean±SD)68.4±26.763.5±23.30.25
Haemoglobin, g/dL (mean±SD)13.0±1.812.9±1.50.69
Creatinine, mg/dL (mean±SD)1.1±0.31.1±0.30.72
Platelets, 105/mL (mean±SD)225.8±75.5207.9±75.40.19
ASA only, n (%)7 (9.7)7 (11.7)0.72
P2Y12 inhibitors only, n (%)3 (4.2)3 (5.0)1.0
Dual antiplatelet therapy, n (%)3 (4.2)2 (3.3)1.0
  • AF, atrial fibrillation; ASA, acetylsalicylic acid; CABG, coronary artery bypass grafting; DOACs, direct oral anticoagulants; eGFR, estimated glomerular filtration rate; HR, heart rate; IDOAC, interrupted direct oral anticoagulant; MI, myocardial infarction; NSTE-ACS, non-ST elevation acute coronary syndromes; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST-elevation myocardial infarction; TIA, transient ischaemic attack; UDOAC, uninterrupted direct oral anticoagulant.